Summary:
- PDS Biotechnology is strategically realigning its clinical pipeline to prioritize the development of PDS0301, a targeted immunotherapy candidate, following promising preliminary data showing a 71% objective response rate in patients with refractory metastatic colorectal cancer.
- The company has made the decision to discontinue its Phase 3 VERSATILE-002 trial for PDS0101, opting to reallocate resources toward the more clinically advanced and higher-potential PDS0301 program to optimize long-term shareholder value and clinical impact.